Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Parathyroid Hormone
Therapeutic Area: Musculoskeletal Product Name: PTH
Highest Development Status: Preclinical Product Type: Peptide
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $69.0 million Upfront Cash: Undisclosed
Deal Type: Series E Financing December 10, 2020
Details:
Rani Therapeutics platform technology converts injectable drugs like PTH and adalimumab into pills. Rani has conducted early human studies with adalimumab and exenatide to confirm high bioavailability with the Rani delivery approach.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): KER-012
Therapeutic Area: Musculoskeletal Product Name: KER-012
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2020
Details:
In Preclinical Studies, KER-012 Increased Trabecular Bone by Reducing Bone Catabolism and Enhancing Anabolism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Calcium Alpha-Ketoglutarate
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
The multi-year study, conducted by the Buck Institute for Research on Aging in aged mice, found that calcium alpha-ketoglutarate (Ca-AKG), a stable form of alpha-ketoglutarate, promotes longer, healthier life associated with a decrease in levels of inflammatory cytokines.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
